Payer or Provider: Two Sides of the Same Coin?

Article

Payer or Provider: Two Sides of the Same Coin?

September 08, 2022
Authors
Topics

Welcome to the September 2022 edition of our Monthly Insight Series. This month we discuss our inaugural Payer Report Series, which is launching soon.

doctors

Greetings from San Mateo!

Our inaugural Payer Report Series is launching soon! The first report of this series, coming out later this month, will be a two-part payer landscape report featuring 1) a landscape overview and 2) in-depth yet succinct profiles on six of the largest vertical payers: Humana, Centene, Elevance Health (formerly Anthem), Cigna, UnitedHealth Group, and CVS Health. 

As these payers continue to grow and “verticalize,” they are capturing an increasingly large share of national healthcare expenditures and will impact how every stakeholder in our health system does business. But what exactly are they doing and how successful are their verticalization efforts? 

We combed through the data and financial sources to deliver a report sure to elevate our sponsors’ understanding of how each vertical payer’s overall structure, recent healthcare services investments, business size and footprint, and financial model will impact the overall organization. If you want to know how your company’s priorities and business operations need to adapt as these vertical payers grow, be sure to keep an eye on your inbox for the release of this incredibly valuable report!

Sneak Peek

UnitedHealth Group is arguably the most extensive and integrated vertical payer to date with a high “verticalization maturity” – the Optum Brand is more than a decade in the making and has a huge network of both employed healthcare practitioners and value-based provider arrangements

UnitedHealth is investing in oncology care services, with a focus on oncology value-based programs, dedicated Optum cancer clinics, the Optum Cancer Centers of Excellence program, and its Optum infusion pharmacies

Optum Insight sells extensive datasets and analytics offerings, helping to make Optum (for now) the leader in providing healthcare information among its vertical payer rivals

We can’t wait to share this report with you soon! As always, please reach out with any comments or questions you have.

All the best...
-- HMP Market Access Insights Team

The Latest

Easier access to oncology pathway recommendations encourages oncologists’ usage and considerations of these recommendations. Our new 2024-2025 Oncology Clinical Pathways Impact Report reveals the variability in pathway integration and usage.
Article
Easier Pathway Access, Greater Pathway Usage

Easier access to oncology pathway recommendations encourages oncologists’ usage and considerations of these recommendations. Our new 2024-2025 Oncology Clinical Pathways Impact Report reveals the variability in pathway integration and usage.

Cindy Chen
Our 2024-2025 Oncology Clinical Pathways Report, set for release in December, will provide insights into the most impactful pathways and key factors manufacturers should assess as the oncology pathways landscape continues to evolve.
Article
Unlocking Oncology Pathway Impact: Beyond Lives Covered to Real Prescribing Influence

As Oncology pathway programs continue to become more prominent in the marketplace, manufacturers are being challenged to assess how influential a specific pathway is.

Daniel Buchenberger
Podcast
Community Oncology Practice Economics - Podcast Part 3 of 3

In the final part of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore emerging models for success in oncology practice economics.

Lee Blansett